Comparison of Remimazolam and Etomidate As Induction Agents for Electroconvulsive Treatment
Summary
The goal of this clinical trial is to find if patients would awaken quickly after electroconvulsive treatment when remimazolam is used compared to etomidate. It will also learn about the efficacy of remimazolam. The main questions it aims to answer are: Will using remimazolam as an induction agent for ECT provide sufficient therapeutic effects? Additionally, when compared to etomidate, will remimazolam lead to a quicker return of spontaneous respiration and faster eye opening after the seizure? Participants will: Remimazolam and etomidate will be used in a random order, each administered once for the induction of anesthesia in ECT. Blood pressure, heart rate, and other vital signs will be monitored during the treatment, and the duration of the seizure as well as the shock energy used to induce the seizure will be recorded.
Timeline
- Start
- 2023-04-28
- Primary completion
- 2024-01-31
- Completion
- 2024-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etomidate | Small molecule | 0.15 mg/kg | Intravenous |
| Subject | Etomidate | Small molecule | 0.2 mg/kg | Intravenous |
| Subject | Remimazolam | Small molecule | 0.12 mg/kg | Intravenous |
| Subject | Remimazolam | Small molecule | 0.15 mg/kg | Intravenous |